Trial Registered

E-nitiate completes Phase 2 QY201 pharmacokinetic study in teen eczema

The 24-patient trial in adolescents with moderate to severe atopic dermatitis has finished, setting up a Phase 3 study already enrolling by invitation.

E-nitiate Biopharmaceuticals completed a Phase 2a pharmacokinetics, safety, and efficacy study of oral QY201 tablets in 24 adolescents with moderate to severe atopic dermatitis.

By AppliedXLJuly 17, 2026Trial NCT07712536

Executive Summary

A Phase 2 pharmacokinetics and safety study of an oral small-molecule candidate in adolescents with moderate to severe atopic dermatitis has completed, testing dosing and tolerability in a younger population before broader confirmatory testing.
The sponsor has already moved the same drug into a Phase 3 trial that is enrolling by invitation, indicating the adolescent pharmacokinetic work was designed to run alongside, rather than gate, later-stage development.
The drug enters an atopic dermatitis field crowded with approved oral JAK inhibitors and injectable biologics, none of which the trial names as a direct comparator, so the study's value lies in dosing and safety data rather than a competitive head-to-head.
No efficacy or pharmacokinetic results have posted yet, leaving the dosing rationale for the Phase 3 program to be confirmed once this study's data become public.

The study

NCT07712536 enrolled 24 adolescents aged 12 to under 18 with moderate to severe atopic dermatitis, defined by a vIGA-AD score of 3 or higher, an EASI score of 16 or higher, and body-surface involvement of at least 10%. The trial started June 4, 2025, and reached its primary completion date on December 19, 2025, a run of 198 days. Its registered primary outcome measures plasma concentrations of QY201 at multiple time points and population pharmacokinetic profiles through Day 29, the design of a dose-characterization study rather than a confirmatory efficacy trial. NCT07712536

Design and population

The trial used randomized allocation across two arms with quadruple masking, and enrolled patients who had an inadequate response to topical corticosteroids, topical calcineurin inhibitors, or had an indication for systemic therapy. Patients on prior JAK inhibitors, including ruxolitinib, tofacitinib, baricitinib, upadacitinib, or abrocitinib, or on biologics such as dupilumab, were excluded from receiving those therapies within 12 weeks of baseline, isolating QY201's own pharmacokinetic and safety signal from residual drug effect. NCT07712536

Ahead of the data

The sponsor has already advanced QY201 into a Phase 3 trial, NCT07180511, which is enrolling by invitation with a target of 460 patients and a primary completion date of May 18, 2027. An earlier Phase 1/2 study of QY201 in the same indication, NCT05525715, targeted 260 patients but now carries an Unknown status. Running the adolescent pharmacokinetic study alongside an already-enrolling Phase 3 trial indicates the sponsor set the adult dosing regimen with enough confidence to proceed before adolescent data matured. NCT07712536

The competitive field

Atopic dermatitis is a heavily worked indication: 406 trials have tested small-molecule candidates in the disease, and the broader field includes approved oral JAK inhibitors such as AbbVie's upadacitinib and Pfizer's abrocitinib, alongside biologics including Regeneron's dupilumab and Sanofi's amlitelimab, none of which the dossier identifies as a direct comparator to QY201. QY201's own molecular target is not identified in the trial record, so no first-in-class or mechanism-isolation claim applies; the drug's competitive position rests on its modality and its adolescent-focused development path rather than a differentiated mechanism. Against a field this mature, with multiple approved options already addressing moderate to severe disease, a Phase 3 program's value will turn on whether QY201 can reproduce EASI and itch-reduction effects comparable to approved options in a pediatric population where treatment options remain narrower than in adults. NCT07712536

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.